Accepted for/Published in: Interactive Journal of Medical Research
Date Submitted: Apr 1, 2025
Open Peer Review Period: Apr 2, 2025 - May 28, 2025
Date Accepted: Jun 5, 2025
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Safety and efficacy of aspirin and indobufen in the treatment of arteriosclerotic cardiovascular disease: a systematic review and meta-analysis
ABSTRACT
Background:
The pathogenesis of atherosclerotic thrombosis primarily involves platelet activation and aggregation, making antiplatelet therapy the cornerstone of treatment for such diseases.
Objective:
This meta-analysis aimed to compare the safety and efficacy of aspirin and indobufen in antiplatelet therapy for patients with arteriosclerotic cardiovascular disease.
Methods:
We searched the Cochrane Library, PubMed, EMBASE, Web of Science, and the Chinese Wanfang databases. The literature was screened according to predefined inclusion and exclusion criteria. Relative risk (RR) was used to assess the magnitude of risk associated with exposure.
Results:
Eighteen clinical trials with a total of 12981 patients were included in this study. Compared with aspirin, indobufen reduced the risk of (1) bleeding events (RR 0.54; 95% CI: 0.41–0.71; P < 0.0001), (2) BARC 2/3/5 bleeding (RR 0.50; 95% CI: 0.26–0.94; P = 0.03), (3) adverse cardiovascular events (RR 0.43; 95% CI: 0.30–0.61; P < 0.00001), and (4) myocardial infarction (RR 0.60; 95% CI: 0.41–0.89; P = 0.01). However, there were no significant differences between the two groups in terms of MACCEs, stroke, or cardiovascular mortality.
Conclusions:
Compared to aspirin, indobufen demonstrated better safety and was not inferior to aspirin in terms of efficacy, with superior results in some aspects. Further studies with larger sample sizes or longer follow-up periods may provide additional evidence. Clinical Trial: This study is registered with PROSPERO (CRD42024588250) and was conducted in accordance with the 2020 version of the PRISMA statement
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.